课件：从循证医学__看待他汀强效安全的辩证统一.ppt

* Adapted by permission from Elsevier Inc. This slide shows similar data to the previous but for the more stringent LDL-C goal of 70 mg/dL for very high-risk patients. For each statin, a greater proportion of patients achieved the LDL-C treatment goal as the 剂量 was increased. Patients were also more likely to achieve the treatment goal if they had lower baseline LDL-C levels. In fact, for each statin, there were significant trends towards a greater likelihood of achieving the LDL-C goal of 70 mg/dL with increasing 剂量 of statin (p0.001) 和 lower baseline LDL-C level (p0.001). * Adapted by permission from Elsevier Inc. * * * * VOYAGER：比较瑞舒伐他汀(RSV)与辛伐他汀(SIM)降低LDL-C的疗效 与RSV 5 mg 比较 与RSV 10 mg 比较 与RSV 20 mg 比较 与RSV 40 mg 比较 SIM 10 mg 0 SIM 40 mg 0 SIM 80 mg 0 SIM 80 mg 319 SIM 10 mg 321 *** SIM 20 mg 6001 *** SIM 40 mg 314 *** SIM 20 mg 1090 *** SIM 40 mg 1084 *** SIM 80 mg 323 *** SIM 80 mg 943 *** SIM 40 mg 315 *** SIM 20 mg 489 *** 治疗组间LDL-C自基线平均变化百分比的差异(95% CI) 剂 量 n 0 5 -5 10 -10 -15 -20 -25 15 20 25 倾向于瑞舒伐他汀 倾向于辛伐他汀 ***p0.001 与辛伐他汀相比 注：瑞舒伐他汀40mg尚未在中国注册 Nicholls SJ, et al. Am J Cardiol. 2010;105(1):69-76. 对基线LDL-C水平≤160mg/dL患者的分层分析:LDL-C达标(100 mg/dl)情况 ?代表少于10例患者. NA=无可用数据 基线 LDL-C 水平 (mg/dL): 130 130–160 瑞舒伐他汀 阿托伐他汀 辛伐他汀 ? NANA NA ? 剂量 (mg) 0 20 40 60 80 100 5 10 20 40 10 20 40 80 10 20 40 80 LDL-C达标(100 mg/Dl) 的患者（%） NA 注：瑞舒伐他汀40mg尚未在中国注册 Nicholls SJ, et al. Am J Cardiol. 2010;105(1):69-76. 基线 LDL-C水平 ≥160mg/dL的高危患者：LDL-C 达标(100 mg/dl)情况 瑞舒伐他汀 阿托伐他汀 辛伐他汀 剂量(mg) 0 20 40 60 80 100 5 10 20 40 10 20 40 80 10 20 40 80 LDL-C达标(100 mg/Dl) 的患者（%） 注：瑞舒伐他汀40mg尚未在中国注册 Nicholls SJ, et al. Am J Cardiol. 2010;105(1):69-76. 对基线LDL-C水平≤160mg/dL患者的分层分析:LDL-C达标(70 mg/dl)情况 NA 0 瑞舒伐他汀 阿托伐他汀 辛伐他汀 ? NANA NA 0 ? 剂量 (mg) 基线LDL-C 水平 (mg/dL): 130 130–160 0 20 40 60 80 100 5 10 20 40 10 20 40 80 10 20 40 80 LDL-C达标(70 mg/dL) 患者 (%) ?代表少于10例患者. NA=无可用数据 注：瑞舒伐他汀40mg尚未在中国注册 Nicholls SJ, et al. Am J Cardiol. 2010;105(1):69-7